Growth Hormone Protocol
TabimorelinComplete Dosing & Administration Guide
An investigational oral growth hormone secretagogue that stimulates GH release through ghrelin receptor activation, though development was discontinued due to drug interaction concerns.
Dose Range
100-500mg
Frequency
Once daily
Route
Oral (capsule or solution)
Cycle Length
4-6 weeks
Dosing
How much
do I take?
Timing
Best time to take
Evening or before bedtime (mirrors natural GH secretion patterns)
With food?
Take Tabimorelin on an empty stomach for optimal absorption, or with a light meal if GI discomfort occurs. Avoid heavy meals within 30 minutes of dosing.
If stacking
If combining Tabimorelin with other peptides or supplements, space administrations by at least 15-30 minutes when possible. Consult with a healthcare provider before combining with prescription medications.
Adjusting Your Dose
Increase if
- +You've tolerated the current dose for the recommended period without significant side effects
- +Therapeutic goals haven't been met at the current dose level
- +Your healthcare provider recommends dose escalation based on your response
- +Lab work or clinical assessments support a higher dose
Decrease if
- -Side effects are bothersome or impacting daily life despite management strategies
- -You experience any signs of an adverse reaction
- -Lab results indicate the need for dose reduction
- -Your healthcare provider recommends a lower dose based on your response
Signs of right dose
- ✓Therapeutic goals being met with minimal side effects
- ✓Stable and consistent response to treatment
- ✓Lab values or clinical markers trending in the right direction
- ✓Good tolerance with manageable or absent side effects
Dosing Calculator
Calculate Your Exact Dose
Step 1: Peptide Weight
Find the weight printed on your peptide vial label
Look here!
The peptide weight is printed on the label
Look here!
The weight is on the label
Administration
How do I
use it?
Reconstitution
What you need
- •Tabimorelin in its prescribed form
- •Clean, dry storage container
- •Measuring device if applicable (oral syringe, measuring cup)
- •Calendar or reminder app for dosing schedule
Injection
Route
Not applicable — oral formulation only
Best sites
- •N/A — oral administration only, not administered by injection
Technique
- 1.Tabimorelin is taken orally in capsule or solution form, not via injection
- 2.Take with or without food as directed
- 3.Swallow capsules whole with water
- 4.Follow exact dosing instructions on prescription label
Storage
Signs of degradation
Safety
Is it
safe?
Safety Profile
Tabimorelin is an oral GHS-R agonist with preclinical and early clinical data indicating dose-dependent appetite stimulation (potentially problematic for weight-conscious users) and transient blood glucose elevation due to GH's insulin-antagonistic effects. No human safety database exists beyond Phase 1/2 studies—efficacy and long-term safety profile in humans remain incompletely characterized. Potential risks include carpal tunnel syndrome (documented with chronic GH therapy), arthralgias, and theoretical tumor growth acceleration, though these are extrapolated from GH physiology rather than directly observed in limited human exposure.
Safety information is limited to rat and limited human Phase 1/2 data; no Phase 3 efficacy trials have been completed. GH secretagogue class effects (appetite stimulation, glucose dysregulation) are expected based on mechanism, but individual tolerability variability is substantial. Long-term human safety data beyond 12 weeks does not exist—any use should be considered experimental with careful clinical monitoring including fasting glucose and IGF-1 levels.
Common Side Effects
Experienced by some users
Headache
Mild to moderate headache onset within 1-2 hours of dosing, typically frontal or temporal. Reported in ~30% of users in early clinical trials. Usually improves with repeated dosing as body tolerates ghrelin stimulation.
Management: Take with food to slow absorption and reduce intensity. Ibuprofen or acetaminophen (500 mg) effective if needed. Stay well-hydrated—dehydration worsens headaches. Divide dose (AM + PM instead of single dose) if tolerated. Most headaches diminish by day 3-5 with continued use.
Nausea
Mild to moderate nausea onset within 30 minutes to 2 hours post-dose. Reflects ghrelin receptor stimulation in the chemoreceptor trigger zone. Reported in ~20-25% of users. Usually mild and self-limited but can be distressing.
Management: Take immediately after eating (not on empty stomach) to buffer gastric irritation. Ginger (500 mg capsule or tea) is highly effective and natural. Ondansetron (4-8 mg) or metoclopramide (10 mg) work if ginger insufficient. Ensure adequate hydration. Most users report nausea resolves by day 3-5 as chemoreceptor tolerance develops.
Appetite stimulation
Ghrelin mimicry causes progressive appetite increase starting day 2-3. Peak hunger typically days 7-14. Mediated via NPY/AgRP pathways in lateral hypothalamus. Expected and intended effect reflecting proper ghrelin receptor activation.
Management: If weight gain is undesired, portion control at meals is essential—use smaller plates and eat slowly. Increase protein proportion to promote satiety. Avoid keep snacks available in visible locations. Time dosing away from peak hunger (early morning on empty stomach, not pre-meal). Increase aerobic activity to offset caloric surplus. This effect usually stabilizes by week 3-4.
Dizziness
Mild to moderate lightheadedness or vertigo onset within 30-90 minutes post-dose. Likely reflects acute cardiovascular changes from GH stimulation and ghrelin receptor activation. Usually mild and transient.
Management: Avoid driving or operating heavy machinery for 1-2 hours after dosing. Sit or lie down if dizziness occurs. Stay well-hydrated. Slow positional changes—rise from sitting slowly. Blood pressure monitoring may reveal mild changes. Dizziness usually diminishes by day 2-3 as tolerance develops.
Dry mouth
Xerostomia develops gradually within 1-4 hours post-dose. Results from ghrelin receptor stimulation affecting salivary gland function and increased metabolic rate. Usually mild but can be bothersome.
Management: Increase overall fluid intake to 2.5-3 liters daily. Sip water frequently throughout day. Sugar-free gum/lozenges stimulate saliva production. Avoid caffeinated beverages (worsen dehydration). Mouth rinse with water before bed. Most cases resolve by day 3-7 with consistent hydration.
Stop and Seek Help If
- ×Severe or worsening side effects that don't improve with dose adjustment or supportive care
- ×Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- ×Your healthcare provider recommends discontinuation based on your clinical response
- ×Development of any new medical condition that may be contraindicated with Tabimorelin
- ×Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- ×Abnormal lab results or clinical markers that suggest adverse effects
Tabimorelin should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Interactions
With other peptides
- ✓May be used together under medical guidance.
- ✓May be used together under medical guidance.
- ✓May be used together under medical guidance.
With medications
- !Strong CYP3A4 inhibitors (itraconazole, ritonavir, clarithromycin) — tabimorelin itself inhibits CYP3A4, creating bidirectional interaction risks - Use with caution—discuss with your healthcare provider.
- !CYP3A4 substrates (statins, certain antiarrhythmics, immunosuppressants) without careful monitoring - Use with caution—discuss with your healthcare provider.
With supplements
- ✓Multivitamins - Generally safe to take alongside Tabimorelin. Space doses apart if taking oral formulations to ensure optimal absorption.
- ✓Electrolyte supplements - Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Want the Full Picture?
View the complete Tabimorelin research profile including mechanism of action, clinical studies, effectiveness timeline, and FAQ.
View Full Tabimorelin Profile